共 30 条
[21]
OHNO N, 1987, CHEM PHARM BULL, V35, P2180
[22]
OKAZAKI M, 1995, BIOL PHARM BULL, V18, P1320, DOI 10.1248/bpb.18.1320
[23]
OZINSKY A, 2000, P NATL ACAD SCI USA, V95, P9825
[24]
ACTIVATION OF THE COMPLEMENT-SYSTEM BY (1-]3)-BETA-D-GLUCANS HAVING DIFFERENT DEGREES OF BRANCHING AND DIFFERENT ULTRASTRUCTURES
[J].
JOURNAL OF PHARMACOBIO-DYNAMICS,
1992, 15 (06)
:277-285
[25]
Tsuzuki A, 1999, DRUG DEVELOP RES, V48, P17, DOI 10.1002/(SICI)1098-2299(199909)48:1<17::AID-DDR3>3.0.CO
[26]
2-N
[28]
Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells
[J].
JOURNAL OF CLINICAL INVESTIGATION,
1996, 98 (01)
:50-61
[29]
Xia Y, 1999, J IMMUNOL, V162, P2281
[30]
Yadomae T., 1996, RECENT RES DEV CHEM, V1, P23